Orphalan announces US commercial launch of Cuvrior™ for the treatment of Wilson disease
20 avr. 2023 07h00 HE
|
Orphalan
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and tolerant to penicillamine — Oral administration offers dosing flexibility and...
CryptoCurrencyWire Designated Official Newswire for Paris Blockchain Week
17 mars 2023 15h21 HE
|
InvestorBrandNetwork (IBN)
LOS ANGELES, March 17, 2023 (GLOBE NEWSWIRE) -- via CryptoCurrencyWire -- IBN (“InvestorBrandNetwork”), a multifaceted communications organization with 50+ brands, is pleased to announce...
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma pour Noema Pharma, une biopharma ciblant les maladies graves du système nerveux central
07 mars 2023 04h00 HE
|
Jeito Capital
Jeito Capital co-dirige un financement de 104 millions d’euros pour Noema Pharma, une biopharma ciblant les maladies graves du système...
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central nervous system disorders
07 mars 2023 04h00 HE
|
Jeito Capital
Jeito Capital co-leads a EUR 104 million financing in Noema Pharma, a clinical-stage biopharma company targeting debilitating central...
Paris, France Receives the 2023 Sustainable Transport Award for Progress on Accessibility, Sustainability, and Inclusion
06 févr. 2023 10h45 HE
|
ITDP
NEW YORK, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The Institute for Transportation and Development Policy (ITDP) and the Sustainable Transport Award Committee are proud to announce Paris, France as the...
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars
06 déc. 2022 07h00 HE
|
Jeito Capital
Jeito Capital renforce son soutien à Pulmocide en participant à un nouveau financement de 52 millions de dollars Ce nouveau tour de table permettra d’accélérer le développement clinique et...
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients with cancer
22 nov. 2022 05h00 HE
|
Jeito Capital
Jeito Capital co-leads EUR 50 million financing in CatalYm, a clinical-stage biopharma company developing novel immunotherapies for patients...
Jeito Capital investit dans CatalYm Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie
22 nov. 2022 05h00 HE
|
Jeito Capital
Jeito Capital investit dans CatalYm société biopharmaceutique allemande spécialisée en immuno-oncologie Jeito Capital co-dirige un financement de série C de 50 millions d'euros avec Brandon...
Smart Immune appoints world-class Clinical Advisory Board
21 nov. 2022 07h00 HE
|
Smart Immune
Smart Immune appoints world-class Clinical Advisory Board PARIS, France, November 21, 2022 – Smart Immune SAS, a clinical-stage biotechnology company developing ProTcell™, a pioneering new approach...
Coliving Startup Cohabs Joins Forces With Leading Real Estate Investors to Accelerate Growth
18 nov. 2022 15h46 HE
|
Cohabs
BRUSSELS, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cohabs, a Brussels-based company specializing in coliving, announces the entry into its capital of three new institutional investors: global real estate...